More 'Chemo-Free' Treatment Options In Follicular Lymphoma Care
- Immune‑based therapies are rapidly reshaping follicular lymphoma care, with multiple chemotherapy‑free options—like tafasitamab‑based and epcoritamab‑based combinations—now available for relapsed disease.
- Since these treatments work differently and haven’t been compared head‑to‑head, choosing among them increasingly depends on patient‑specific factors such as prior therapies, side‑effect profiles, and practical considerations.
- Across both relapse and frontline settings, the field is moving toward personalized, immune‑driven strategies that may reduce reliance on chemotherapy while expanding durable, targeted treatment options for patients.
Today, however, the field is moving increasingly toward treatments that harness the immune system and target lymphoma cells more precisely, rather than relying on traditional chemotherapy.
Read More
What Does the Data Say?
One of the clearest examples of this shift is the emergence of chemotherapy-free treatment combinations for patients whose lymphoma has returned after initial therapy. In 2025, the FDA approved tafasitamab in combination with lenalidomide and rituximab for patients with relapsed or refractory follicular lymphoma. Tafasitamab is an antibody that targets CD19, a protein found on many lymphoma cells.Epcoritamab, a bispecific antibody that helps a patient’s T cells recognize and attack lymphoma cells, is also approved in combination with lenalidomide and rituximab for relapsed or refractory FL. Both approaches are chemotherapy-free and have demonstrated meaningful improvements compared with lenalidomide and rituximab alone.
“Patients with relapsed follicular lymphoma now have access to regimens approved by the Food and Drug Administration, including (a) Epcoritamab monotherapy, (b) Mosunetuzumab monotherapy, and (c) Epcoritamab plus Lenalidomide and Rituximab. Furthermore, bispecific antibodies are being investigated as frontline treatments for treatment-naïve follicular lymphoma, and encouraging results have been reported for Epcoritamab and Mosunetuzumab,” Dr. Deng added.
WATCH: What Patients Should Know About the Rise of Bispecific Antibodies in Follicular Lymphoma
Which Treatment Path Is Better for Patients?
This raises an important question: which approach is better?
Right now, there is no simple answer. Tafasitamab-based and epcoritamab-based treatments have not been directly compared with one another in a head-to-head clinical trial, and they work through different immune mechanisms. They also differ in how they are given, their potential side effects, and the practical considerations involved in treatment.
As more of these therapies become available, treatment decisions will increasingly involve choosing among several effective options rather than simply choosing between different chemotherapy regimens.
Earlier Chemo-Free Options
The movement toward chemotherapy-free treatment is also happening earlier in the course of follicular lymphoma. Clinical trials are testing bispecific antibodies in combination with established treatments such as rituximab and lenalidomide, and some studies are asking whether bispecific antibodies can be incorporated into initial treatment rather than being reserved for relapse.
Other trials are combining these immune therapies with newer targeted drugs and other immune-based treatments. The goal is to determine whether patients can achieve deep and durable remissions while avoiding traditional chemotherapy altogether.
“Over the next few years, several clinical trials should read out that will likely demonstrate a new paradigm for the frontline treatment of FL. As more tolerable therapies are developed, important questions such as when to initiate treatment may also be re-examined,” NYU Langone medical oncologist Dr. Catherine S. Diefenbach tells SurvivorNet.
Expert Resources for Follicular Lymphoma Patients
- Follicular Lymphoma: Understanding Your Treatment Options & Why There’s No Single Path
- All About Follicular Lymphoma: A Common Type of Non-Hodgkin Lymphoma
- Coping with Refractory Follicular Lymphoma: New Treatment On The Horizon
- Bispecific Antibodies For Follicular Lymphoma: Increased Use And The Possibility of A Cure
Other Treatment Options
Several other approaches are changing the treatment landscape. CAR T-cell therapy has become an important option for selected patients with relapsed or treatment-resistant FL and can produce deep, durable remissions in some patients.
New targeted therapies and combinations are also being studied. Researchers are increasingly exploring whether these therapies can be used together, or in sequence, to keep the lymphoma under control for longer periods while minimizing treatment burden.
Chemo’s Still Here
This does not mean that chemotherapy is obsolete. Chemotherapy remains an effective treatment for many people with FL, and there are situations in which it may still be the best choice. The right strategy depends not only on the treatment itself, but also on when treatment is needed, how the lymphoma is behaving, what treatments have already been given, and what matters most to the patient.
The biggest change may be that we are moving away from thinking of follicular lymphoma treatment as a fixed sequence of chemotherapy regimens.
Instead, we are entering an era in which several effective, chemotherapy-free options can be selected and sequenced for the individual patient.
We still have important questions to answer, including which immune-based strategies provide the longest-lasting benefit, how best to sequence these treatments, and whether some of these approaches should eventually replace chemotherapy altogether.
A Promising Future
For patients with follicular lymphoma, this is an exciting time.
Treatment is becoming more personalized, increasingly immune-based, and less dependent on traditional chemotherapy. The challenge now is learning how to use these growing numbers of treatments at the right time, for the right patient, and with the right goals in mind.
Learn more about SurvivorNet's rigorous medical review process.
